一次抗体と二次抗体-抗-エピトープタグ、免疫測定、Cas 9 » MonoRab™ ウサギモノクローナル抗体製品 » MonoRab™ Anti-Nivolumab Antibody (33H4), mAb, Rabbit

MonoRab™ Anti-Nivolumab Antibody (33H4), mAb, Rabbit

*This product has been discontinued!*
The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A01988-40, MonoRab Anti-Nivolumab Antibody (40F11), mAb, Rabbit.
A01987
Ask us a question
Overview
Specificity The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A01988-40, MonoRab Anti-Nivolumab Antibody (40F11), mAb, Rabbit.
Host Species Rabbit
Immunogen Nivolumab
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-0.1 µg/ml

Properties
Form Lyophilized
Storage Buffer Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Rabbit IgG
Clonality Monoclonal
Clone ID 33H4
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Background
Target Background Nivolumab is a fully human monoclonal IgG4 antibody that is approved by the U.S. Food and Drug Administration for the treatment of bladder cancer. It binds to the programmed cell death protein 1 (PD-1) on the surface of activated T cells. Nivolumab functions as PD-1 inhibitor for targeted immunotherapy.GenScript MonoRab™ Anti-Nivolumab Antibody (33H4), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Nivolumab.
Synonyms Rabbit monoclonal to Opdivo

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.